21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯
| 中文名称 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 |
|---|---|
| 中文同义词 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯;醋酸四烯物;21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 100G;醋酸四烯物(3TR);21-乙酰氧基孕甾-1,4,9(11),16-四烯-3,20-酮;16-四烯-3,20-二酮-21-醋酸酯;布地奈德杂质对照品6;2-((8S,10S,13S,14S)-10,13-二甲基-3-氧代-6,7,8,10,12,13,14,15-八氢-3H-环戊二烯并[A]菲-17-基)-2-氧代乙基 乙酸酯 |
| 英文名称 | 3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate |
| 英文同义词 | Pregna-1,4,9(11),16-tetraen-21-ol-3,20-dione 21-acetate;21-Acetoxypregna-1,4,9(11),16-tetrene-3,20-dione;3,20-Dioxopregna-1,4,9(11),16-tetrene-21-ol acetate;21-(Acetyloxy)-pregna-1,4,9(11),16-tetraene-3,20-dione;Pregna-1,4,9(11),16-tetraene-3,20-dione,21-(acetyloxy)-;Tetraen-acetic acid complex;3,20-dioxopregna-1,4,9(11),16-tetraen-21-yl acetate;[2-[(8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate |
| CAS号 | 37413-91-5 |
| 分子式 | C23H26O4 |
| 分子量 | 366.45 |
| EINECS号 | 253-497-3 |
| 相关类别 | 化工产品-有机化工;添加剂1;杂质对照品;原料药;化工原料;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;原料中间体 |
| Mol文件 | 37413-91-5.mol |
| 结构式 |  |
21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 性质
| 熔点 | 173-175°C |
|---|---|
| 沸点 | 534.6±50.0 °C(Predicted) |
| 密度 | 1.21±0.1 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | 二甲基亚砜：100 mg/mL（272.89 mM） |
| 形态 | 固体 |
| 颜色 | 白色至类白色 |
| InChI | InChI=1S/C23H26O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h7-10,12,17-18H,4-6,11,13H2,1-3H3/t17-,18-,22-,23-/m0/s1 |
| InChIKey | UFEOMHFPJREVTP-PTRHGPIFSA-N |
| SMILES | C1(=O)C=C2[C@](C)(C=C1)C1[C@]([H])([C@@]3([H])[C@@](CC=1)(C)C(C(=O)COC(C)=O)=CC3)CC2 |
醋酸四烯物(21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯,3TR)是合成曲安奈德、地塞米松、布地奈德等甾体药物的重要中间体21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione 是 delta 9,11 类固醇类合成的中间体 (intermediate)，如 Vamorolone (HY-109017)。delta 9,11 steroids 是糖皮质激素的修饰后的产物，具有抗炎 (anti-inflammatory) 特性。delta 9,11 类固醇类可以用作保护细胞损伤(脂质过氧化)和抑制新生血管的试剂。
Δ9,11 derivatives are designed and developed to stably incorporate into cell membranes and inhibit lipid peroxidation without glucocorticoid or mineralocorticoid activities, thus avoiding side effects associated with traditional corticosteroids. VBP15 acts as a lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability.
用途
地塞米松、倍他米松、确炎舒松的中间体。安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-136340 | 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione | 5 mg | 312元 | |
| 2024/04/30 | HY-136340 | 21-羟基孕甾-1,4,9(11),16-四烯-3,20-二酮-21-醋酸酯 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione | 37413-91-5 | 10mg | 500元 |